Idorsia, the Swiss biotech firm, faces significant financial challenges despite recent progress in product development, with its share price plummeting 36.94% to EUR 1.426. However, the company has received US approval for the antihypertensive drug aprocitentan and presented new data on the sleep aid daridorexant, which could enhance sales in the medium term. Investors are keenly observing the upcoming weeks to see if Idorsia can stabilize its finances while capitalizing on its growth potential.